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Abstract
Background:  The human endogenous retrovirus HERV-K(HML-2) family is associated with
testicular germ cell tumors (GCT). Various HML-2 proviruses encode viral proteins such as Env
and Rec.
Results: We describe here that HML-2 Env gives rise to a 13 kDa signal peptide (SP) that harbors
a different C-terminus compared to Rec. Subsequent to guiding Env to the endoplasmatic reticulum
(ER), HML-2 SP is released into the cytosol. Biochemical analysis and confocal microscopy
demonstrated that similar to Rec, SP efficiently translocates to the granular component of nucleoli.
Unlike Rec, SP does not shuttle between nucleus and cytoplasm. SP is less stable than Rec as it is
subjected to proteasomal degradation. Moreover, SP lacks export activity towards HML-2 genomic
RNA, the main function of Rec in the original viral context, and SP does not interfere with Rec's
RNA export activity.
Conclusion:  SP is a previously unrecognized HML-2 protein that, besides targeting and
translocation of Env into the ER lumen, may exert biological functions distinct from Rec. HML-2 SP
represents another functional similarity with the closely related Mouse Mammary Tumor Virus that
encodes an Env-derived SP named p14. Our findings furthermore support the emerging concept of
bioactive SPs as a conserved retroviral strategy to modulate their host cell environment, evidenced
here by a "retroviral fossil". While the specific role of HML-2 SP remains to be elucidated in the
context of human biology, we speculate that it may be involved in immune evasion of GCT cells or
tumorigenesis.
Background
The human genome harbors about 8% of sequences of
retroviral origin, remnants of different exogenous retrovi-
rus infections of the germ line genome that occurred mil-
lions of years ago. The human endogenous retrovirus
(HERV) family HERV-K(HML-2), henceforth HML-2,
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family contains recently formed proviral loci. The number
of mutations along the proviral coding sequence remains
low for evolutionarily younger HML-2 proviral loci. Some
of those proviruses contain nearly intact open reading
frames (ORFs) with a few or no mutations [1-4] and func-
tional proteins in vitro [5-11]. Though, while engineered
HML-2 proviruses display ex vivo infectivity and ability to
form new proviruses [12,13], no replication-competent
HERV-K(HML-2) variant was identified in the human
population so far. The HML-2 family was also shown to
produce retrovirus-like particles budding from teratocarci-
noma and melanoma derived cell lines [14,15]. HERVs
have been implicated in several human pathologies
including cancers and autoimmune diseases [reviewed in
[16,17]]. HML-2 has gained special attention because of
its association with testicular germ cell tumors (GCT), the
most common tumor type among young men in western
industrialized countries. Indeed, HML-2 expression is
strongly up-regulated in early stages of GCT [18]. Eighty-
five percent of GCT patients, more precisely seminoma
patients, display a specific immune response to HML-2
Gag and Env proteins [19,20]. Since tumor remissions are
associated with a decreased titer, while progression or
relapse coincide with stable or elevated titers, antibody tit-
ers correlate with clinical manifestation of the disease
[21,22].
Two major types of HML-2 proviruses exist in the genome.
Type 1 proviruses differ from full-length type 2 proviruses
by a 292 bp deletion within the boundary of pol and env
genes [23,24]env mRNA from type 2 proviruses is sub-
spliced to create a rec mRNA that encodes the Rec (for-
merly cORF) protein, a functional homologue to Rev and
Rex, the RNA-binding nuclear export proteins of HIV and
HTLV, respectively [25-29]. Rec has been reported to inter-
act with nuclear promyelocytic leukemia zinc finger
(PLZF) protein that has been implicated in leukemogene-
sis and spermatogenesis, and disturbs germ cell develop-
ment in Rec-transgenic mice [30-32]. Type 1 sequences
lack the rec splice donor site that is located in the 292 bp
stretch [27]. An alternative splice donor site located just
upstream of the 292 bp stretch is instead used to splice
np9 mRNA. The corresponding Np9 protein shares only
14 aa with Rec and Env [33,34].
HERV-K(HML-2) displays significant sequence similari-
ties with Mouse Mammary Tumor virus (MMTV), particu-
larly for the env gene [35]. Both HML-2 and MMTV belong
to the Betaretroviruses that include retroviruses formerly
classified as type B and D [36]. MMTV also encodes a func-
tional homologue of HIV Rev and HML-2 Rec, termed
Rem [37,38]. Rem contains the complete and unusually
long signal peptide of MMTV Env precursor, termed of
p14/SPRem. The latter was shown to translocate into nucle-
oli of murine T cell lymphoma cells [39,40]. Specific func-
tions of p14/SPRem remain to be elucidated.
Characterization of presecretory eukaryotic and prokaryo-
tic signal peptides (SPs) defined the features essential for
their function, such as hydrophobicity and a common
sequence for the site of cleavage from its mature protein
by signal peptidase [41-43]. For many cellular proteins,
SP's unique function is to target nascent polypeptide
chains into the endoplasmic reticulum (ER) membrane
and entry into the translocon. While much is known
about subsequent transport of the secretory protein to its
correct subcellular location, the fate of signal peptides
after their cleavage from the pre-proteins is still unclear
and turns out to be complex. SP degradation kinetic and
longevity are variable. In some cases, SPs are thought to be
readily degraded, making them undetectable in vitro.
Some SPs are further processed by an ER intramembrane
cleaving protease, the signal peptide peptidase and
released into the cytosol where they can accumulate [44-
46]. Importantly, according to this emerging concept,
these "longer-living" SPs, liberated into the cytosol, could
promote post-targeting functions in the cell, such as cell
signaling or regulation [47].
The orientation of SPs across the ER membrane defines
two types of signal peptides. Type I SPs anchor the pro-
teins by transferring it across the ER membrane, leaving
the C-terminus of the protein in the cytoplasmic side of
the ER. Conversely, type II SPs retain the N-terminus of
the protein in the cytosol [45,48]. Retroviral Env SPs are
type II membrane proteins. In most cases, after polypep-
tide chain transfer into the translocon, SP is cleaved from
the Env precursor by signal peptidase and subsequently
degraded. Env monomers integrate into the ER membrane
and undergo further maturation steps [49,50]. However,
besides MMTV p14/SPRem, several exceptions exist: HIV-1
gp120 Env SP remains bound to calnexin in the ER mem-
brane and is inefficiently cleaved very late in the matura-
tion process [51,52]. For Human Foamy Virus (HFV), SP
mediates specificity of Env interaction with HFV capsid
and is found in purified particles [53].
More recently, biochemical studies showed that p14/
SPRem targets Rem to the ER, is then cleaved off and accu-
mulates in the nucleoli. Interestingly, this process is inde-
pendent of cleavage by signal peptide peptidase [54].
We describe here for the first time the HERV-K(HML2)
Env precursor SP as a 13 kDa signal peptide. By examining
features of HML-2 SP, such as subcellular localization,
nucleocytoplasmic shuttling, protein stability and RNA
export activity, we established functional dissimilarities to
Rec. Our data suggest that HML-2 SP exerts a Rec-inde-
pendent function. Furthermore, the finding of a long-Retrovirology 2009, 6:17 http://www.retrovirology.com/content/6/1/17
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lived SP for HML-2 reveals another similarity between the
closely related HML-2 and MMTV retroviruses, thus fur-
ther establishes their close relationship on the functional
level.
Results
SPs among the Retroviridae
To gain better insight into the organization of retroviral
SPs, we first compared the SP regions of prototype mem-
bers of each Retroviridae class and related endogenous ret-
roviral members, using PHOBIUS, SignalP and TMD [55-
57]. As depicted in Figure 1, Retroviridae SPs vary signifi-
cantly in length, with the shortest one being the 15 aa long
HIV-2 SP and the longest one being the 148 aa long HFV
SP. Diverse prototypes of Lentiviruses, including primate
and ungulate Lentiviruses, underline that such heteroge-
neity in SP length also exists among different members of
the same class. All SPs analyzed share a characteristic tri-
partite composition [58]. The central hydrophobic core
(h), critical for targeting and insertion into the ER mem-
brane [42], encompasses between 11 and 22 residues. The
C-terminal extremity (c) is a small polar region that deter-
mines the signal peptidase cleavage site and is well con-
served among all retroviruses analyzed, with the exception
of the HFV prototype. Of note, the N-terminal extremity
(N), which is not involved in protein insertion and trans-
location, is very little conserved in amino acid sequence
and length [59]. For HERV-K(HML-2), as well as for the
other Betaretrovirus prototypes, SP N-extensions consist of
an unusually long sequence varying from 61 to 78 resi-
dues.
HML-2 SP sequence motifs
HERV-K(HML-2) Env is synthesized as a classical retrovi-
ral envelope protein. In the ER, the Env precursor under-
goes a first cleavage by the signal peptidase releasing the
90 kDa Env precursor which then follows the maturation
pathway to the Golgi where it is further cleaved by a furin-
like endoprotease into two N-glycosylated domains, a 55
kDa surface subunit (SU) and a 39 kDa transmembrane
subunit (TM) (A. Ruggieri, unpublished data). In addition
to SU and TM, an accessory protein Rec is encoded by a
smaller mRNA resulting from env mRNA subsplicing. The
first exon of Rec largely overlaps with the env SP coding
sequence in that it comprises amino acids 1 to 87 of Env.
The second exon of Rec is translated from a different read-
ing frame. The resulting 18aa C-terminus is different in
sequence from either the C-terminus of SP or Env. With
regard to the resulting protein, Rec mRNA splicing occurs
just upstream of the SPase cleavage site (Figure 2A). Con-
trary to MMTV Rem, Rec does not contain the complete SP
sequence.
In order to determine conservation of SP among HML-2
proviruses and its sequence relationship to Rec, we com-
pared relevant sequence portions of six HML-2 loci that
could potentially encode full-length Env [13], the
sequence of recently engineered HML-2 Envs, HERV-
KCON/Phoenix [12,13], representative of a functional and
"infectious" HML-2 Env, and the Rec sequence as previ-
ously reported [27] (Figure 2B). The sequences were
almost identical with each other, with complete identity
between HERV-K(HML-2.HOM), an almost intact HML-2
provirus located on chromosome 7 [60], and the "infec-
tious" HERV-KCON [12]. Comparison of the 96 aa long SP
with the 105 aa long Rec showed that both proteins share
the identical N-terminal 87 aa, whereas the C-terminal 9
and 18 aa for SP and Rec, respectively, are unrelated in
sequence (Figure 2B) for reasons described above. By
analogy with previously characterized Rec [27,61], HML-
2 SP harbors two conserved motifs: an arginine-rich puta-
tive nuclear localization signal (NLS; aa 13–20) and a leu-
cine-rich putative nuclear export signal (NES; aa 54–60).
Additionally, HML-2 SP contains domains characteristic
for cellular SPs: (i) a positively charged long N-extension
(residues 1–75), (ii) a hydrophobic h domain (residues
76–90) and (iii) a short polar domain (residues 91–96)
containing characteristic helix-breaking proline and gly-
cine residues as well as small uncharged residues in posi-
tion -3 and -1 adjacent to the h domain [58,62]. HML-2
SP therefore displays a tripartite structure characteristic of
SPs and contains an unusually long N-extension bearing
putative trafficking motifs. The similarities between HML-
2 SP and Rec proteins, in terms of length and sequence,
prompted us to investigate functional similarities and dif-
ferences between the two proteins.
HML-2 SP-RFP fusion proteins can localize in nucleoli
We first determined the subcellular localization of SP and
Rec. To this end, three SP expression constructs where gen-
erated by cloning SP sequences of variable length
upstream of the mrfp gene coding for monomeric Red Flu-
orescent Protein (mRFP) (Figure 3A). The first construct,
named SP75-RFP, included only the HML-2 SP N-exten-
sion sequence (aa 1–75) that bears the NLS and NES and
that is common with Rec. SP96-RFP (aa 1–96) corre-
sponded to the full-length HML-2 SP sequence. To pre-
vent or diminish signal peptidase cleavage during
synthesis of SP96-RFP, we deleted the C-terminal two aa
residues (GA) of the HML-2 SP, giving rise to construct
SP94-RFP. Deletion of those two aa was based on a consen-
sus sequence for signal peptidase cleavage, in which small
uncharged residues in position -3 and -1, including a gly-
cine residue, are thought to be important for cleavage
[62]. Proper protein expression from SP96/94/75-RFP pre-
cursor proteins was verified by Western Blot (Figures 3B
and 4B). Figure 3B shows a Western Blot analysis of HeLa
cells expressing for 48 hours either mRFP or SP75-RFP,
probed with an anti-mRFP polyclonal antibody. The
mRFP protein is subjected to proteolytical degradation, asRetrovirology 2009, 6:17 http://www.retrovirology.com/content/6/1/17
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Domain organization of SPs of selected retroviruses Figure 1
Domain organization of SPs of selected retroviruses. The tripartite composition of retroviral SPs was analyzed using 
PHOBIUS [55], SignalP [56] and TMD [57]. Characteristic domains in representative exogenous and endogenous prototypes of 
each Retroviridae class are shown. Betaretroviruses are further classified based on an earlier retrovirus taxonomy. See text for 
details on N-terminal extremity (N); central hydrophobic core (h); C-terminal extremity (c). Numbers indicate start and end 
positions, in aa, of each domain. RSV: Rous Sarcoma Virus; MMTV: Mouse Mammary Tumor Virus; HERV-K(HML-2): Human 
Endogenous Retrovirus type K subfamily HML-2; JSRV: Jaagsiekte Sheep Retrovirus; MPMV: Mason Pfizer Monkey Retrovirus; 
HERV-W: Human Endogenous Retrovirus type W; MLV Mo: Moloney Murine Leukemia Virus; HERV-FRD: Human Endog-
enous Retrovirus type FRD; HTLV-1: Human T-cell Leukemia Virus 1; HFV: Human Foamy Virus. HIV-1/HIV-2: Human Immu-
nodeficiency Virus 1 and 2; SIVmac: Simian Immunodeficiency Virus, acaque isolate; Visna: Maedi-Visna Virus.
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Figure 2 (see legend on next page)
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indicated by an 18-19 kDa band. Probing SP fusion
contructs with an anti-SP polyclonal antibody confirmed
the absence of cleaved SP in the SP94-RFP construct, in
which the signal peptidase cleavage site had been
mutated. As observed in control experiments (Figure 3B),
mRFP fusion protein is likely proteotically cleaved in the
mRFP moiety or in the linker region between mRFP and
SP sequences. Unspecific cleavage likely occured in this
linker region for SP75-RFP and SP94-RFP proteins, giving
rise to bands with noticeably different sizes (Figure 4B).
We compared the subcellular localization of these three
SP-RFP fusion contructs to that of the previously
described GFPcORF, a biologically active Rec fused to
Green Fluoresccent Protein (GFP) [61]. HeLa cells were
transiently transfected, fixed after 24 hours and analyzed
by confocal microscopy. HeLa cells expressing either
mRFP or eGFP were transfected and analyzed as control.
Both mRFP and eGFP were homogeneously distributed in
the cell (data not shown). As expected for a protein shut-
tling between cytoplasm and nucleoli, GFPcORF was
found in both cytoplasm and nucleoli, as confirmed by
counterstaining of cells with antibodies against B23/
nucleophosmin or C23/nucleolin, two major proteins of
the granular component and the dense fibrillar compo-
nent of the nucleolar compartment [63]. SP75-RFP was
strongly enriched in the nucleoli of transfected cells and
could also be detected in the cytoplasm, however, at sig-
nificantly lower amounts than GFPcORF that was visible
only after over-exposure (Figure 3C; and data not shown).
These observations revealed that the 75 aa long N-exten-
sion domain of HML-2 SP, that is identical to the N-termi-
nal part of Rec, efficiently targets an mRFP fusion moiety
to nucleoli resulting in a subcellular distribution similar,
but not identical, to that of Rec. The full-length SP fusion
protein, SP96-RFP, displayed an unexpected phenotype. In
about half of the transfected cells, subcellular localization
of SP96-RFP was suggestive of the ER network, probably
indicating that SP96-RFP was following the ER pathway
and that HML-2 SP was still able to achieve its primary
function, namely translocating proteins into the ER mem-
brane. For the remaining transfected cells SP96-RFP was
found in the nucleoli (Figure 3C). As the cells expressing
the different SP fusion constructs were transiently trans-
fected, we hypothesized that the ER pathway was satu-
rated and that for this fraction of cells proteins were
translated on free ribosomes in the cytosol. Interestingly,
SP94-RFP also displayed a subcellular localization identi-
cal to that of SP75-RFP and GFPcORF, likewise accumulat-
ing in nucleoli. The synthesis pathway followed by SP94-
RFP protein is also difficult to predict as the SP precursor
protein lacks a proper signal peptidase cleavage site. SP75-
RFP and SP94-RFP are likely synthesized in the cytosol.
Taken together, our results confirm that HML-2 SP
sequence is capable of translocating a precursor protein to
the ER and can target a cytosolic protein to the nucleoli.
HML-2 SP accumulates in the granular component of 
nucleoli
After cleavage from the native polypeptidic chain, SPs are
usually released from the ER membrane and subsequently
degraded. In some cases and in particular when the N-
extension is long, SPs can be released into the cytosol and
exert biological activities [45]. As above results suggested
that HML-2 SP contains a functional NLS in the N-termi-
nal extension, we addressed whether HML-2 SP localizes
to nucleoli when cleaved from the Env precursor protein.
To exclude the possibility that the observed localization of
SP94-RFP, and in some cases that of SP96-RFP, was due to
an aberrant conformation generated by the C-terminal
RFP fusion, we determined HML-2 SP's localization after
cleavage from its natural Env precursor. To facilitate anal-
ysis of SP in the Env context and to eliminate Rec produc-
tion, we introduced silent mutations in rec splice donor
and acceptor sites at nt positions 6708–6716 and 8404–
8414, respectively (numbers refer to the HERV-K(HML-
2.HOM) sequence [60] (EnvΔRec; Figure 4A). Presence of
env  and  rec  transcripts was analyzed by RT-PCR using
Comparison of HERV-K(HML-2) SP and Rec sequences Figure 2 (see previous page)
Comparison of HERV-K(HML-2) SP and Rec sequences. (A) env mRNA encodes an Env precursor protein that is 
cleaved in the ER by signal peptidase releasing SP. In the Golgi, the Env precursor is further processed and cleaved by a furin-
like endoprotease to give rise to surface (SU) and transmembrane (TM) subunits. rec mRNA is a splice product of env mRNA 
and encodes Rec. The first exon of Rec overlaps with SP while the second exon is translated from a different reading frame. 
SD/SA: rec splice donor and acceptor sites. (B) SP and Rec amino acid sequence alignment. The human genome contains six 
proviruses with complete Env ORFs [13]. HERV-K(HML-2.HOM) is an almost intact provirus located on chromosome 7p22.1 
(Env_HOM) [60]. Chromosomal localizations of other Env encoding loci are indicated. HERV-K113 (Env_K113) and HERV-
K115 (Env_K115) are two polymorphic proviruses located on chromosomes 19p12 and 8p23.1, respectively [4]. The alignment 
also includes HERV-KCON, a recently engineered "infectious" provirus [12], and the Rec sequence [27]. Rec exon 1 (aa 1–87) is 
also found in SP while the second exon of Rec (aa 88–105) is translated from a different reading frame. N: N-extension (aa 1–
75); h: hydrophobic h domain (aa 76–90); C: polar domain (aa 91–96); -3,-1:position of small uncharged residues. By analogy 
with motifs previously characterized in Rec, a putative arginine-rich nuclear localization signal (NLS; aa 13–20) and a leucine-
rich nuclear export signal (NES; aa 54–60) are present in HML-2 SP.Retrovirology 2009, 6:17 http://www.retrovirology.com/content/6/1/17
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Subcellular localization of HML-2 SP fusion protein Figure 3
Subcellular localization of HML-2 SP fusion protein. (A) Schematic representation of SP fusion proteins. N-extensions 
of HML-2 SP of different length (aa 1–75; aa 1–94; aa 1–96) were cloned in frame with the monomeric red fluorescent protein 
(mRFP). NLS: putative nuclear localization signal; NES: putative nuclear export signal; h: hydrophobic core. (B) Western blot 
analysis of HeLa cells transiently expressing mRFP and SP75-RFP. The Western blot was stained with anti-mRFP antibody. 
mRFP-expressing cells produce mRFP with an approximate molecular weight of 30 kDa. An 18–19 kDa proteolytic product can 
also be is detected. An SP75-RFP construct produces SP-RFP fusion protein and (RFP) degradation products. (C) Confocal sec-
tions showing SP75-RFP, SP96-RFP and SP94-RFP fluorescence in red and co-immunostained nucleolar markers B23/nucleophos-
min or C23/nucleolin in green. The lower right panel shows GFPcORF/Rec fluorescence in green and nucleolar markers in red. 
Co-localization of proteins is indicated in yellow. Images show HeLa cells fixed 24 hours post-transfection. White bar = 10 μm.Retrovirology 2009, 6:17 http://www.retrovirology.com/content/6/1/17
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Figure 4 (see legend on next page)
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appropriate primers. While env  transcripts were readily
observed, no transcript corresponding to rec mRNA could
be detected (data not shown). Hence, the EnvΔRec con-
struct predominantly produces SP and Env but no Rec.
Furthermore, Env maturation and trafficking were not
affected by the introduced point mutations, and as pre-
dicted, as more env mRNA was available for translation,
EnvΔRec-expressing cells showed an increased amount of
Env (data not shown).
To detect HML-2 SP, we raised a rabbit polyclonal antise-
rum against the N-terminal 19 aa of HML-2 Env (anti-SP).
That anti-SP antibody detected a protein of approx. 15
kDa, as predicted for Rec, in Env-expressing cells (Figure
4B). In EnvΔRec-expressing cells, only SP with a molecular
weight of approx. 13 kDa, but not Rec, could be detected.
Interestingly, at high levels of wild-type Env expression,
besides Rec, another smaller and fainter band correspond-
ing to the size of SP could be detected, indicating that SP
is produced at low steady-state levels also from the wild-
type HML-2 Env precursor. However, the anti-SP antibody
did not allow detection of the Env precursor, likely
because of conformational inaccessibility of the recog-
nized epitope.
We used EnvΔRec-expressing cells to determine the sub-
cellular localization of HML-2 SP and compared it to that
of Rec. Considering that the epitope designed for anti-SP
production is also present in Rec, the antibody thus
detecting both SP and Rec in Env-expressing cells, we pre-
ferred to employ a Rec expression plasmid [31]. Subcellu-
lar localization of HML-2 SP was first examined by
biochemical cell fractionation experiments. Following
hypotonic lysis, cells were separated by sucrose sedimen-
tation into cytoplasmic, nuclear, nucleoplasmic and
nucleolar fractions, and equal relative protein amounts
were analyzed by Western blotting. Distribution of the
cytoplasmic enzyme GAPDH served as quality control. As
shown in Figure 4C, SP and Rec were both found in the
cytoplasmic and nuclear fractions. Nuclear fractionation
further revealed that HML-2 SP and Rec were predomi-
nantly located in the nucleolar fraction. This biochemical
analysis was further corroborated by confocal microscopy
of EnvΔRec- and Rec-expressing cells. Using the anti-SP
antibody, SP and Rec were found enriched in nucleoli.
More precisely, co-localization with marker protein B23
showed that SP and Rec, when expressed without tags,
located primarily to the granular component of nucleoli
(Figure 4D and 4E). Taken together, biochemical and
microscopic analyses revealed that HML-2 SP is an addi-
tional HML-2 protein produced in HML-2 Env-expressing
cells that translocates to the granular component of nucle-
oli.
HML-2 SP nucleolar localization is sensitive to inhibition 
of transcription
Treatment of cells with Actinomycin D (ActD), an RNA
polymerase II inhibitor, causes redistribution of nucleolar
proteins, such as B23 and C23, into the nucleoplasm
[64,65]. ActD treatment also influences localization of
some retroviral proteins. Among those, HIV-1 Rev and
HTLV Rex are redistributed to the cytoplasm while MMTV
SP translocates from nucleoli to nucleoplasm [64-67]. To
further characterize the nucleolar localization of HML-2
SP and Rec proteins we applied 5 μg/ml ActD on SP75-
RFP, SP94-RFP and GFPcORF-expressing cells (Figure 5).
Two hours before the start of the experiment, cells were
pre-incubated with 100 μg/ml of the protein synthesis
inhibitor cycloheximide (CHX) to follow existing SP and
Rec protein pools in the absence of new protein produc-
tion. CHX remained present during the two hours of ActD
treatment. Expectedly, addition of ActD caused dispersion
of nucleoli markers B23 and C23 from nucleoli to nucle-
oplasm. SP75-RFP also dispersed from nucleoli to nucleo-
HERV-K(HML-2) SP localizes to nucleoli Figure 4 (see previous page)
HERV-K(HML-2) SP localizes to nucleoli. (A) Schematic representation of proteins encoded by Env and EnvΔRec expres-
sion vectors. Env-expressing cells produce Env and Rec. Both contain the epitope recognized by the anti-SP antibody (black 
bars). The EnvΔRec construct harbors silent point mutations (asterisks) in splice donor (SD) and splice acceptor (SA) sites, 
eliminating rec mRNA splicing and Rec protein production. (B) Western blot analysis of HeLa cells transiently expressing Env, 
EnvΔRec and SP96/94/75-RFP. The Western blot was stained with anti-SP antibody. Env-expressing cells produce the 15 kDa Rec 
protein and a lower amount of SP (asterisk) with an approximate molecular weight of 13 kDa. In EnvΔRec-expressing cells only 
SP is detected. SP96/94/75-RFP constructs produce SP-RFP fusion proteins and (RFP) degradation products. SP96-RFP releases SP 
while SP75-RFP and SP94-RFP do not due to engineered deletions (see text). An SP-like band produced by SP75-RFP is very likely 
an unspecific mRFP degradation product (see text and Figure 3B). (C) Western blot analysis of fractionated Hela cells tran-
siently expressing Env and EnvΔRec. Cell lysates were probed with anti-SP and anti-GAPDH antibodies, the latter verifying 
proper separation of fractions. L: full lysate; Cy: cytoplasm; Nu: nucleus; Np: nucleoplasm; Ni: nucleoli. (D and E) Confocal sec-
tions of HeLa cells fixed 24 hours post-transfection and co-immunostained with anti-SP for detection of SP or Rec (in red), and 
with antibodies detecting B23/nucleophosmin or C23/nucleolin (in green). White bar = 10 μm. (D) SP distribution in EnvΔRec-
expressing cells. (E) Rec distribution in Env-expressing cells. The merge panels show, in yellow, co-localization of both SP and 
Rec with B23/nucleophosmin in the granular component of nucleoli.Retrovirology 2009, 6:17 http://www.retrovirology.com/content/6/1/17
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Effect of actinomycin D treatment on SP distribution Figure 5
Effect of actinomycin D treatment on SP distribution. Confocal analysis of HeLa cells, 24 hours post-transfection, 
treated (or not) with 5 μg/ml Actinomycin D (ActD/no ActD) for 2 hours. Prior and during the experiment, cells were incu-
bated with CHX at 100 μg/ml. Cells expressing SP75-RFP (A), SP94-RFP (B) or GFPcORF (C) were fixed and co-immunostained 
for B23/nucleophosmin nucleoli marker. White bar = 10 μm.
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plasm, however, maintained a distinct nucleolar
enrichment (Figure 5A). Similarly, GFPcORF inefficiently
dispersed from the nucleoli and, in addition, accumulated
in the nucleoplasm in a bright punctuate pattern as well
as diffusely in the cytoplasm (Figure 5C). Interestingly,
SP94-RFP completely abandoned the nucleoli and
enriched in the nucleoplasm and cytosol (Figure 5B).
These results demonstrated that the nucleolar localisation
of a precursor protein harboring HML-2 SP is as sensitive
to ActD-mediated dispersion as that of cellular markers of
granular and dense fibrillar nucleoli components, and
revealed further differences in the subcellular localization
between Rec and SP fusion proteins upon ActD treatment.
HML-2 SP is subjected to proteasomal degradation
Although HML-2 SP and Rec proteins share large parts of
their amino acid sequence and both localize to nucleoli,
the steady state protein levels in the context of HML-2 Env
expression were significantly different (Figure 4B). To
address the reason for these different expression levels we
compared the stability of HML-2 SP and Rec proteins.
CHX (100 μg/ml) was added to Env- and EnvΔRec-
expressing cells 16 hours post-transfection and pre-exist-
ing SP and Rec molecules were chased for up to 8 hours.
At various time points, cells were collected and analyzed
by Western blotting using the anti-SP antibody. β-actin
served as loading control. As shown in Figure 6, the
amounts of SP present at time point 0 rapidly decreased,
resulting in an estimated half-life of the protein of not
more than 2 hours. In contrast, cellular Rec levels
remained constant over the entire 8 hour chase period. In
addition to SP and Rec, we noted higher molecular weight
bands in both Env- and EnvΔRec-expressing cells, includ-
ing a protein band slightly larger than SP. Those proteins
most likely resulted from saturation and bypassing of the
ER pathway due to large-scale mRNA synthesis and pro-
tein production following transient transfection. Transla-
tion then initiates on free ribosomes in the cytosol
producing polypeptides of variable length that each con-
tain the N-terminal epitope used for anti-SP generation.
To better understand the molecular mechanism responsi-
ble for reduced HML-2 SP stability, when compared to
Rec, proteasome inhibition was achieved by addition of
carbobenzoxy-L-leucyl-L-leucyl-L-leucinal (MG132) to a
final concentration of 10 μM. MG132 was added to Env-
and EnvΔRec-expressing cells 16 hours post-transfection.
Cells were collected every hour and analyzed by Western
blot using the anti-SP antibody. As shown in Figure 7, for
EnvΔRec-transfected cells, at the start of the incubation
and consistent with our previous results, expression of SP
was difficult to detect. Treatment with MG132 for one
hour drastically increased (at least ten-fold) the amount
of SP, and SP levels remained high over 8 hours of incu-
bation in presence of proteasome inhibitor. Above men-
tioned cytosolic Env-translation products also
accumulated in the course of the treatment. To confirm
that the difficulty in detecting SP at a steady state in Env-
expressing cells was due to its degradation by the proteas-
ome, we applied MG132 to Env-expressing cells. As
Determination of half-life of HML-2 SP Figure 6
Determination of half-life of HML-2 SP. HeLa cells expressing either EnvΔRec or Env were incubated, 16 hours post-
transfection, with the translation inhibitor CHX at 100 μg/ml. SP and Rec molecules were chased for up to 8 hours. Every 
hour, cells were collected and analyzed by Western blot using anti-SP. Cellular β-actin was analyzed as a loading control. 
Larger-sized protein bands correspond to cytosolic translation products due to saturation effects (see text).
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Degradation of HML-2 SP by the proteasome Figure 7
Degradation of HML-2 SP by the proteasome. HeLa cells expressing EnvΔRec or Env were incubated, 16 hours post-
transfection, with proteasome inhibitor MG132 at 10 μM. Cells were collected every hour for, in total, 8 hours and analyzed by 
Western blotting using anti-SP. Cellular β-actin was analyzed as a loading control. Larger-sized protein bands, including the 
protein band slightly larger than SP in the left-hand Western blot, correspond to cytosolic translation products that are due to 
saturation effects (see text).
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shown in Figure 7, at the start of the experiment, SP was
barely detectable but accumulated after MG132 treat-
ment. In this case, SP levels increased gradually during the
8 hours of treatment. A doublet band of approximatively
14 kDa could also be detected and accumulated in both
Env- and EnvΔRec-expressing cells. This observation
raised the possibiblity of further processing of HML-2 SP
by signal peptide peptidase that is thought to cleave SPs
within the hydrophobic transmembrane region. A cleav-
age in HML-2 SP h domain (residues 76–90) would
remove around 12 to 14 aa, corresponding to approxi-
mately 1 kDa. Biochemical studies are required to charac-
terize whether HML-2 SP is released in the cytosol after
signal peptide peptidase cleavage or extraction from the
lipidic membrane as observed recently for p14/SPRem [54].
Altogether, these results reveal that HML-2 SP has a half-
life of less than two hours following cleavage from the Env
precursor, and is degraded by the proteasome.
HML-2 SP is not a nucleo-cytoplasmic shuttle protein and 
lacks RNA export activity
The observed differences in protein stability and respon-
siveness to ActD suggested that HML-2 SP and Rec may
have distinct biological properties. Rec's activity in export
of genomic RNA strictly depends on functional NLS and
NES motifs. While our above analysis demonstrated effi-
cient nuclear import of SP, functionality of the putative
NES sequence in SP (see Figure 2) was not addressed. We
therefore examined nucleo-cytoplasmic shuttling of SP,
compared to Rec, in an interspecies heterokaryon assay
[68]. Heterokaryons were formed by fusing transfected
human cells with untransfected mouse cells. Mouse nuclei
could be distinguished because of a characteristic punctu-
ated pattern following staining with Hoechst 33258 [69]
(Figure 8A). HeLa cells were transfected with SP75-RFP,
SP94-RFP or GFPcORF expression plasmids and co-cul-
tured with mouse NIH3T3 cells 16 hours post-transfec-
tion. 24 hours later, protein synthesis was blocked by
CHX treatment and fusion was induced. Syncytia forma-
tion was verified by May-Grünwald-Giemsa staining (not
shown). Rec (GFPcORF) was readily detected in human
and mouse nuclei, confirming its nucleo-cytoplasmic
shuttling activity. SP75-RFP also shuttled into mouse
nucleoli, even more efficiently than Rec/GFPcORF, dem-
onstrating that the NES motif in SP75-RFP is functional.
However, SP94-RFP was never found in mouse nucleoli,
suggesting that in the context of the full-length sequence,
the NES motif has lost its functionality. Thus, heter-
okaryon assays demonstrated that full-length HML-2 SP
carries a non functional NES. HML-2 SP therefore does
not appear to be a nucleo-cytoplasmic shuttle protein.
We also asked whether HML-2 SP could export HML-2
mRNA in a manner similar to Rec. To export HML-2 tran-
scripts to the cytoplasm, Rec specifically binds to the Rec-
responsive element, K-RRE, located within the U3 region
of the HML-2 long terminal repeat [28,29]. To quantify
RNA export activity, HeLa cells were transfected with the
chloramphenicol acetyl transferase (CAT) reporter plas-
mid pDM128/K-RRE [29]. Cytoplasmic expression of CAT
protein was measured in response to co-expressed Rec and
EnvΔRec. pDM128/K-RRE carries the cat gene within an
intron under control of the SV40 promoter flanked down-
stream by the K-RRE sequence [29]. Presence of a K-RRE-
binding RNA export factor thus leads to export of
unspliced CAT mRNA to the cytoplasm and CAT protein
synthesis. 24 hours post-transfection, the cytoplasmic lev-
els of CAT were determined by CAT ELISA. As shown in
Figure 8B, co-transfection of pDM128/K-RRE and expres-
sion plasmids for Rec alone, or for HML-2 Env, resulted in
a 4- and 6-fold, respectively, increase of CAT expression
over background. As expected, an RNA export-defective
Rec mutant (RecΔNES), carrying a mutated NES motif
[70] displayed no significant RNA export activity. We next
tested HML-2 SP's export activity by co-transfecting the
reporter plasmid along with EnvΔRec expression plas-
mids. No significant induction of CAT production was
detected for SP. We thus conclude that HML-2 SP, in con-
trast to Rec, lacks HML-2 mRNA export activity.
Since SP and Rec both reside in nucleoli, and since SP is
highly similar in sequence to Rec, we also addressed
whether HML-2 SP can affect Rec's RNA export activity.
However, co-expression of Env with increasing concentra-
tions of EnvΔRec, together with constant amounts of the
reporter vector, had no effect on CAT levels (Figure 8B).
These results suggest that even if SP accumulates in the
nucleoli, it does not sequester HML-2 mRNA away from
Rec and thus can not compete with Rec for mRNA bind-
ing. This indicates that, despite its high sequence similar-
ity to Rec, SP exerts (a) function(s) distinct from Rec.
Discussion
This study demonstrates a previously unrecognized pro-
tein encoded by HERV-K(HML-2), namely a 13 kDa SP
that is produced by cleavage of the HML-2 Env precursor.
Sequence analysis revealed that HML-2 SP is common to
HERV-K(HML-2) type 2 proviruses and that the first 87
residues, out of 96, are shared with Rec, the protein
exporting HERV-K(HML-2) mRNA out of the nucleus [27-
29]. Like Rec, HML-2 SP is found in the granular compo-
nent of nucleoli. In contrast to Rec, HML-2 SP is rather
short-lived, it is subjected to proteasomal degradation, it
does not shuttle between nucleoli and cytosol, and it does
not export HML-2 mRNA out of the nucleus. These obser-
vations reveal that HML-2 type 2 proviruses encode an
additional Rec-like protein that is functionally distinct
from Rec. Despite its proteasomal degradation, HERV-
K(HML-2) SP is a long-lived protein when compared to
conventional SPs. Thus, in addition to its primary func-Retrovirology 2009, 6:17 http://www.retrovirology.com/content/6/1/17
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Figure 8 (see legend on next page)
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tion of targeting the Env precursor to the secretory path-
way, HML-2 SP traffics to nucleoli after its cleavage from
the Env precursor to exert an independent, yet to be char-
acterized activity.
Considering that HML-2 SP shares 87 of its 96 residues
with Rec, the functional differences between both pro-
teins are remarkable. These differences do not stem from
altered subcellular localization. Surprisingly, while the
nuclear import motif is functional in HML-2 SP, mediat-
ing its transport into the nucleoli, the NES motif, func-
tional and well characterized for Rec, is no longer
functional in HML-2 SP. Shuttle activity, as well as distinct
protein stability, and RNA export inactivity are therefore
probably determined by the HML-2 C-terminal 9 aa that
distinguish SP from Rec. One may argue that reduced half-
life of HML-2 SP, when compared to Rec, hampers its abil-
ity to export HML-2 RNA. Addition of ubiquitin on pro-
tein chains is known to target them to the proteasome
[71,72]. SUMOplot [73] predicts a putative sumoylation
motif between residues 37 and 40 (MKLP) of both Rec
and HML-2 SP. One might hypothesize that this region is
more accessible in SP than in Rec due to differences in the
3D conformation of both proteins. Alternatively, the
unique C-terminus of HML-2 SP may facilitate interaction
with e.g. the ubiqutin ligase system. However, if decreased
protein stability was the limiting factor, HML-2 SP's RNA
export activity would be reduced rather than absent. The
observed nonfunctional NES motif, in combination with
a complete lack of RNA export activity, thus suggests gen-
eral impairment of HML-2 SP in RNA transport.
Signal peptide fragments resulting from processing of sig-
nal peptides by signal peptide peptidases are known to be
released in the cytosol. Such processing could also occur
in the hydrophobic region of HML-2 SP. Recent biochem-
ical analysis of p14/SPRem, also trafficking to nucleoli after
its cleavage, showed that its release was independent of
Signal Peptide Peptidase activity. The release was a time-
and temperature-dependent process, and SPRem/p14 was
found in the nucleolar fraction for at least 90 minutes
[54]. It is currently not known whether MMTV p14/SPRem
and HML-2 SP are processed in the same manner.
The fact that SP sequences are common to HML-2 type 2
proviruses argues for a vital role of SP in the former viral
life cycle. The presented data rule out that HML-2 SP
served to back up or modulate Rec's main function – RNA
export activity. SPs of other viral proteins also exert func-
tions beyond ER targeting during the viral life cycle. In
cases where specific functions could be attributed to the
viral SP, most of these activities relate to the maturation
and function of the respective viral glycoprotein and affect
processes such as Env folding or post-translational modi-
fications (HIV-1 gp120 and Ebola SP) [51,74-76], com-
plex formation with the mature Env glycoprotein (Junin
Virus and Lymphocytic Choriomeningitis Virus), intracel-
lular trafficking, fusion or virus infectivity in general [77-
80]. In HFV, SP affects viral particle assembly and release
[53,81]. When testing potential effects of HML-2 SP on
Env expression, we did not observe post-translational
impairment, as HML-2 Env precursor was efficiently
cleaved in the Golgi into SU and TM subunits, was glyco-
sylated on 8 potential N-glycosylation consensus sites and
was found expressed on the cell surface of human trans-
fected cells (A. Ruggieri, unpublished results). HML-2 SP
therefore does not seem to regulate or delay Env complex
maturation or cell surface expression. However, due to the
lack of infectious HERV-K(HML-2) viral particles one can-
not exclude that HML-2 SP affects Env's fusion functions.
The data presented thus far do not allow us to conclude of
what the former and potentially current biological activity
of HML-2 SP consists. The same is true for a comparison
of HML-2 SP functions with those of the related MMTV
p14/SPRem, especially when considering that both have
not been characterized in great detail, yet. In the context
of human biology, when assuming a causal relationship
between expression of HML-2 gene products and germ
cell tumor development, active immune evasion mecha-
nisms are likely in place to counteract elimination of
HML-2 protein-expressing cells. Tumor cells and virally
Functional differences between HML-2 SP and Rec Figure 8 (see previous page)
Functional differences between HML-2 SP and Rec. (A) Heterokaryon assay. HeLa cells were transfected with SP75-
RFP, SP94-RFP or GFPcORF expression plasmids and co-cultured with mouse NIH3T3 cells. Cells were subsequently treated 
with 100 μg/ml CHX for 1 hour. After induction of cell fusion, cells were fixed and immunostained. Counterstaining with 
Hoechst 33258 served to distinguish human from mouse nuclei (left panels). Arrows indicate NIH3T3 nuclei that accumulated 
SP94/75-RFP or GFPcORF after syncytia formation (right panels). (B) Measurement of HML-2 SP RNA export activity by quanti-
tative determination of chloramphenicol acetyltransferase (CAT). HeLa cells were co-transfected with the CAT reporter plas-
mid pDM128/K-RRE (K-RRE) together with either Rec, Env, RecΔNES, or EnvΔRec expression plasmids. Histogram bars 
represent normalized amounts of CAT as determined by CAT ELISA, indicating export of unspliced CAT mRNA to the cyto-
plasm. Where indicated, 400 ng of Env expression plasmid were co-transfected with increasing amounts of EnvΔRec plasmid 
(100, 200, 300 or 400 ng), and with constant amounts of the CAT reporter vector. All values are given as the mean of at least 
4 independent experiments. Error bars indicate the SEM.Retrovirology 2009, 6:17 http://www.retrovirology.com/content/6/1/17
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infected cells often display significantly reduced human
leukocyte antigen (HLA) cell surface levels, rendering
them prone to attack and lysis by natural killer (NK) cells.
Viruses and tumor cells have therefore evolved various
strategies to interfere with NK cell recognition and activa-
tion [82]. Of note, a key cellular mechanism for evasion
of NK cell lysis involves SPs. SP fragments from cellular
proteins containing long and hydrophilic N-extension
can be presented by HLA molecules following release into
the cytosol, proteasomal degradation, transport into the
ER lumen by the transporter of antigen presentation, and
subsequent presentation to the cell surface [83,84]. Anti-
gen-presenting cells make use of this mechanism to report
biosynthesis of MHC class I molecules to the immune sys-
tem [85]: following proteasomal degradation, SPs of HLA-
A, B and C molecules bind selectively to HLA-E molecules
that present them to the inhibitory receptor (CD94-
NKG2) on NK cells, thereby preventing lysis by NK cells.
Remarkably, human cytomegalovirus (HCMV) makes use
of that escape route via a 9aa signal peptide-derived frag-
ment from the HCMV UL40 glycoprotein [86]. Worth
mentioning, a Rhesus CMV-encoded protein was shown
to interfere, in a signal sequence-dependent manner, with
the MHC-I pathway by preventing completion of heavy
chain translation [87]. Based on its short half-life, due to
the action of the proteasome, one might speculate that
HML-2 SP peptides also re-enter the ER lumen to be pre-
sented by HLA molecules, e.g. by HLA-E to interfere with
NK lysis of HERV-K(HML-2) expressing cells. Thus, HML-
2 SP could be involved in the evasion of GCT cells from
the immune system. Alternatively, HML-2 SP may interact
with other cellular proteins in, for instance, nucleoli to
interfere with cellular processes. Interestingly, MMTV
p14/SPRem has been reported to interact with B23/nucleo-
phosmin [39] that has been attributed with tumor suppre-
sor functions [88]. HML-2 SP may likewise interact with
B23/nucleophosmin and may thus interfere with impor-
tant cellular processes. Building on our initial detection
and characterization of HML-2 SP, future studies will have
to elucidate the mechanism of action of HML-2 SP and
HML-2 SP's potential significance for GCT.
Conclusion
The human endogenous retrovirus family HERV-K(HML-
2) is exceptional for various reasons, among them its pro-
tein coding capacity. We now found that the HERV-
K(HML-2) env gene gives rise to an additional 13 kDa pro-
tein by cleavage of the signal peptide from the Env precur-
sor. The HML-2 SP repesents another functional similarity
with the related exogenous Mouse Mammary Tumor Virus
that likewise encodes a stable signal peptide, adding
another case to the concept of several retroviral SPs having
biological functions besides ER-targeting. HML-2 SP and
HML-2 Rec protein, the latter potentially involved in germ
cell tumorigenesis, are very similar in sequence, except for
the N-terminus. Our results strongly indicate that HML-2
SP lacks several functional features previously reported for
HML-2 Rec. HML-2 SP is therefore expected to exert a dif-
ferent biological function. Besides a distinct function in
the (former) retroviral context, HML-2 SP must also be
considered in the context of human biology. Given the
biological features found for HML-2 SP, and findings for
the MMTV SP, one can hypothesize that HML-2 SP is
involved in immune evasion of GCT cells. HML-2 SP may
also interact with important cellular proteins, thereby
playing a significant role in GCT development. Future
research must address HML-2 SP in greater detail.
Methods
Cell lines, reagents and expression plasmids
HeLa and NIH3T3 cells were maintained in Dubelcco's
modified Eagle medium (Invitrogen) supplemented with
10% fetal calf serum (Biochrom). phCMV-HML2-Env was
derived from phCMV-G, a VSV-G Env expression plasmid
[89] by replacing VSV-G Env sequence with HML-2 Env
sequence. HML-2 env gene was amplified by PCR from
the HERV-K(HML-2.HOM) locus (GenBank accession no.
AF074086) [60] and inserted between the two EcoRI sites
of phCMV-G. pSP75-RFP, pSP94-RFP and pSP96-RFP plas-
mids express respectively the N-extension region (aa 1–
75), the sequence missing the last two aa (aa 1–94) and
the full length sequence (aa 1–96) of HML-2 signal pep-
tide (SP), each fused to monomeric Red Fluorescent Pro-
tein (mRFP). SP sequences were amplified by PCR from
phCMV-HML2-Env and inserted into the Ecl136II site of
pmRFP-N1 multiple cloning site [90]. phCMV-EnvΔRec,
an Env expression vector deficient for splicing of rec
mRNA, was generated by site-directed mutatgenesis
(QuickChange Site-Directed Mutagenesis Kit, Stratagene)
of Rec splice donor and acceptor sites located at aa 85–87
and aa 651–655, respectively, of Env. Integrity of gener-
ated plasmids was verified by sequencing. Expression
plasmids for HML-2 Rec, pEGFP-wtcORF and pSG5-Rec,
were described elsewhere [31,61]. pDM128/K-RRE and
pK7-K-RevDNES vectors [29,70] were kindly provided by
Bryan Cullen. pEGFP-N1 (Clontech) was used as control
for transfection efficiency and for normalization in the
CAT assay.
Antibodies
A rabbit anti-SP antibody was raised against HML-2 Env
signal peptide residues 1–19 (MNPSEMQRKAP-
PRRRRHRN) and was used unpurified at a 1:1,000 dilu-
tion for Western blot analysis and 1:200 for
immunofluorescence. The following antibodies were used
at the indicated concentration: mouse monoclonal anti-
nucleophosmin B23 (Zymed Laboratories, Invitrogen) at
a 1:1,000 dilution for Western blotting and 1:50 for
immunofluorescence; mouse monoclonal anti-nucleolin
C23 (clone MS-3) (Santa Cruz Biotechnology) at a 1:50Retrovirology 2009, 6:17 http://www.retrovirology.com/content/6/1/17
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dilution for immunofluorescence; mouse monoclonal
anti-GAPDH (clone 0411) (Santa Cruz Biotechnology) at
a 1:200 dilution for Western blot analysis; mouse mono-
clonal anti-β actin (clone AC-15) (Sigma) at a 1:10,000
dilution for Western blotting. Horseradish peroxidase-
conjugated secondary antibodies were purchased from
Jackson ImmunoResearch Laboratories (Dianova): goat
anti-rabbit IgG (dilution 1:20,000) and sheep anti-mouse
IgG (dilution 1:30,000). Fluorescent secondary antibod-
ies were purchased from Molecular Probes (Invitrogen)
and used at a 1:2,000 dilution: Alexa Fluor 488 goat anti-
mouse IgG, Alexa Fluor 568 goat anti-mouse IgG, and
Alexa Fluor 568 goat anti-rabbit IgG.
Western blot analysis
Transfected cells were harvested 48 hours post-transfec-
tion and lyzed in cold NP40 lysis buffer (50 mM Tris-HCl
pH8, 150 mM NaCl, 1% NP40) supplemented with pro-
tease inhibitor cocktail (Complete Mini EDTA free,
Roche). Samples were boiled in 5× Laemmli sample
buffer, separated by 15% SDS-PAGE, and transferred onto
Hybond-P membrane (Amersham). Membranes were
blocked with Tris Buffered Saline containing 5% skim
milk and 0.05% Tween 20 (Sigma) overnight at 4°C.
Immunostaining was performed in the same buffer using
appropriate first and secondary antibodies. Protein detec-
tion was performed by using the ECL Plus detection kit
(Amersham) according to the manufacturer's instructions.
Cell fractionation
Cell fractionation was adapted from a protocol by Lam
and Lamond [91] with modifications as described. Thirty
hours after transfection, cells were detached and washed
in pre-warmed PBS. All steps were performed on ice. Cells
were resuspended in RBS-8 buffer (10 mM Tris-HCl
pH7.5, 10 mM NaCl, 8 mM Mg acetate) and incubated on
ice for 30 min. Cells were centrifuged (220 g, 5 min, 4°C),
resuspended in 500 μl RBS-NP40 lysis buffer (10 mM Tris-
HCl pH7.5, 10 mM NaCl, 1.5 mM Mg-acetate, 0.5%
NP40) containing protease inhibitor cocktail and were
then transferred into a pre-cooled Dounce tissue homog-
enizer. After 30 to 50 strokes, the cell suspension was cen-
trifuged (220 g, 5 min, 4°C) to separate the cytoplasmic
fraction from the nuclear pellet. The cytoplasmic fraction
was further centrifuged (5,000 g, 3 × 10 min, 4°C) to
eliminate cell debris. To further purify nuclei, the nuclear
pellet was washed three times in 3 ml of S1 solution (0.25
M sucrose, 10 mM MgCl2, protease inhibitor cocktail).
After the final wash, the nuclear pellet was resuspended in
3 ml of S1 solution and layered over 3 ml of S2 solution
(0.35 M sucrose, 0.5 mM MgCl2, protease inhibitor cock-
tail). The sucrose cushion was centrifuged (1,430 g, 5 min,
4°C). The purified nuclear pellet was resuspended in 500
μl of S2 solution and sonicated (3 × 20 sec on ice). The
sonicated nuclei suspension was layered over 1 ml of S3
solution (0.88 M sucrose, 0.5 mM MgCl2, protease inhib-
itor cocktail) and centrifuged (3,000 g, 30 min, 4°C). The
upper fraction was collected and used as nucleoplasm
fraction; the pellet contained the purified nucleoli. All
extracts were adjusted with 2× Laemmli sample buffer,
sonicated and boiled before measuring protein concentra-
tion.
Immunofluorescence
To assay the subcellular localisation of the signal peptide,
2.5 × 105 HeLa cells were seeded on glass coverslips and
transfected with 2 μg expression plasmids. Twenty-four
hours after transfection, cells were fixed with 4% parafor-
maldehyde in Phosphate Buffered Saline (PBS) for 20 min
and permeabilised with 0.1% Triton X-100 in PBS for 1
min. Cells were washed once with PBS before being
treated with blocking solution (1% goat serum in PBS) for
15 min. All incubations were done at room temperature;
washing steps consisted of three PBS washes of 5 min
each. Cells were incubated with rabbit anti-SP, anti-nucle-
ophosmin B23, anti-nucleolin C23 and appropriate fluo-
rescent secondary antibodies. Finally, coverslips were
mounted using Histoprime (Histogel, Linaris). Fluores-
cent microscopy images were acquired using an LSM 510
confocal laser scanning microscope (Zeiss) and using a
60× oil immersion objective lens. Confocal images were
processed using Adobe Photoshop (Adobe Systems).
Determination of protein half-life
1 × 106 HeLa cells were grown in 60 mm tissue culture
plates. 16 hours post-transfection, cycloheximide (CHX,
Sigma) was added to a final concentration of 100 μg/ml
to terminate protein synthesis. Cells were then collected
every hour until 8 hours later. Cell lysates were prepared
as described above and analyzed by Western blot.
Proteasome inhibition
1 × 106 HeLa cells were grown in 60 mm tissue culture
plates. 16 hours post-transfection, cells were incubated for
8 hours in the presence of 10 mM Carbobenzoxy-L-Leu-
cyl-L-Leucyl-L-Leucinal (MG132, Calbiochem) diluted in
dimethyl sulfoxyde (DMSO, Sigma). Mock samples and
DMSO-treated cells were co-cultured in parallel as con-
trols. Cell lysates were prepared as described above and
analyzed by Western blot.
Heterokaryon assay
2.5 × 105 HeLa cells were transfected with 2 μg pGFPcw-
tORF, pSP75-RFP or pSP94-RFP expression plasmids.
Twenty-four hours after transfection, cells were mixed
with 1 × 106 NIH3T3 cells and seeded onto 1.8 × 1.8 cm
glass coverslips. Twelve hours later, cells were treated with
100 μg/ml CHX for 1 hour, and fusion of cell membranes
was induced by addition of 50% (w/v) polyethylene gly-
col 8000 (Sigma) in DMEM for 2 min at 37°C. Cells wereRetrovirology 2009, 6:17 http://www.retrovirology.com/content/6/1/17
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subsequently washed three times with pre-warmed PBS
and once with DMEM, before being incubated at 37°C for
another 6 hours in the presence of 100 μg/ml CHX.
Finally, cells were fixed for immunostaining as described
above. Human and mouse nuclei were distinguished by
staining with Hoechst 33258 (Sigma) at 0.5 μg/ml in PBS.
Fluorescent microscopy images were acquired using an
LSM 510 microscope (Zeiss). Images were processed using
Adobe Photoshop (Adobe Systems).
CAT ELISA assay
The mRNA export function of the HML-2 signal peptide
was assessed by quantitative determination of chloram-
phenicol acetyltransferase (CAT) in a CAT ELISA assay. 5
× 105 HeLa cells were co-transfected with the CAT reporter
plasmid pDM128/K-RRE and either pSG5-Rec, phCMV-
HML2-Env, pK7-K-RevΔNES (RecΔNES) or phCMV-
EnvΔRec, and pEGFP-N1 as a control for transfection effi-
ciency. The CAT ELISA Kit (Roche) was used according to
the manufacturer's instructions. Briefly, 24 hours after
transfection, cells were lyzed and CAT-containing cell
extracts were added into microplate wells coated with
anti-CAT antibody, followed by addition of a digoxigenin-
labeled anti-CAT antibody, and by addition of a peroxi-
dase-conjugated anti-digoxigenin antibody. After addi-
tion of peroxidase substrate, the absorbance of the
colored reaction product was measured at 405 nm (refer-
ence wavelength 490 nm) by using a microplate reader
ELX-800 (Bio-Tek Instruments). Observed CAT produc-
tion was normalized by using GFP as an internal control.
GFP fluorescence of individual cells was analyzed by flow
cytometry using a FACS Scan (Becton Dickinson).
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